Olopatadina Farto (Olopatadine)

Olopatadine blocks histamine H1 receptors on ocular tissues, preventing the vasodilation and increased permeability that cause allergy symptoms. It also stabilises mast cells, reducing the release of additional inflammatory mediators, which together diminish redness, itching, and swelling in the eye.

The dosing regimen for Olopatadina Farto is determined by the prescribing healthcare professional based on the patient’s condition and response. Typically, one drop is instilled in the affected eye(s) as directed, but the exact frequency and duration should follow the prescriber’s instructions.

Safety data for Olopatadina Farto in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against any unknown risks before prescribing to pregnant or nursing mothers, and discuss alternative options if appropriate.

To order Olopatadina Farto, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Olopatadina combines antihistamine activity with mast‑cell stabilisation, offering both rapid symptom relief and longer‑term control. Compared with agents that act solely as antihistamines or mast‑cell stabilisers, olopatadine may provide broader efficacy with a similar safety profile, making it a versatile option for allergic eye disease.

Olopatadina Farto should be stored at room temperature, below 25 °C, in its original packaging. Protect the container from moisture, direct sunlight and extreme temperature fluctuations to maintain product stability and potency.

Olopatadina Farto is administered as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid, and place the prescribed number of drops into the conjunctival sac. Close the eye gently and avoid blinking excessively for a few seconds.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, corneal ulceration, and a significant increase in intra‑ocular pressure. Patients should seek immediate medical attention if they experience sudden vision loss, intense eye pain, swelling, or systemic allergic symptoms.

Individuals with known hypersensitivity to olopatadine or any excipients in the formulation should avoid using Olopatadina Farto. It is also contraindicated in patients with active ocular infections unless directed by a physician, and caution is advised for those with uncontrolled glaucoma.